PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 128 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2020. The put-call ratio across all filers is 1.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $323,184 | -15.6% | 122,892 | +13.3% | 0.01% | -20.0% |
| Q2 2023 | $382,801 | +23.8% | 108,448 | +8.4% | 0.02% | +15.4% |
| Q1 2023 | $309,204 | -17.2% | 100,072 | +13.3% | 0.01% | -31.6% |
| Q4 2022 | $373,602 | +91.6% | 88,322 | +7.4% | 0.02% | +90.0% |
| Q3 2022 | $195,000 | -6.7% | 82,247 | +12.0% | 0.01% | -9.1% |
| Q2 2022 | $209,000 | +21.5% | 73,424 | +23.0% | 0.01% | +57.1% |
| Q1 2022 | $172,000 | +56.4% | 59,680 | +65.6% | 0.01% | +40.0% |
| Q4 2021 | $110,000 | -55.6% | 36,032 | +1.9% | 0.01% | -58.3% |
| Q3 2021 | $248,000 | +5.1% | 35,360 | +37.3% | 0.01% | 0.0% |
| Q2 2021 | $236,000 | +11.3% | 25,745 | +18.3% | 0.01% | -7.7% |
| Q1 2021 | $212,000 | +9.8% | 21,768 | +15.6% | 0.01% | 0.0% |
| Q4 2020 | $193,000 | +52.0% | 18,828 | +54.5% | 0.01% | +18.2% |
| Q2 2020 | $127,000 | – | 12,186 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
| Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
| WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
| Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
| Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
| Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
| Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
| Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
| Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |